Laguna Diagnostics, a California-based biotechnology firm specializing in blood-based tests for psychiatric conditions, has received its second U.S. patent for innovative biomarkers that enable rapid differentiation between schizophrenia and bipolar disorder. The patent, covering methods to analyze gene expression in blood samples, promises to address a critical gap in mental health care where misdiagnoses are rampant and delays in accurate treatment can span years. This development positions the company in a burgeoning segment of the diagnostics market, valued at around $3 billion annually for schizophrenia and bipolar disorder management, amid rising demand for objective tools in precision psychiatry.
The Patent and Its Technological Foundation
The newly granted patent outlines a diagnostic approach that examines messenger RNA (mRNA) expression levels from 18 specific genes in a patient’s blood. The process involves a multi-step analysis: identifying biomarker patterns, computing probabilities of disorder presence, and classifying the sample against predefined thresholds to categorize patients as having schizophrenia (SZ), bipolar disorder (BD), or being neurologically typical (NC). Performance metrics from validation studies show high reliability, with diagnostic accuracy exceeding 90 percent in distinguishing these conditions, far surpassing traditional subjective evaluations.
This builds on Laguna’s foundational 2023 patent and a 2018 peer-reviewed study in Molecular Neuropsychiatry, which first identified these gene panels through exon microarray analysis of blood from 90 participants across the three groups. The technology shifts diagnostics from prolonged clinical observation—often lasting one to three years—to results obtainable in days, potentially reducing the socioeconomic burdens of untreated or mistreated psychosis, including higher suicide risks and cognitive decline.
Tackling Misdiagnosis in a High-Stakes Field
Schizophrenia affects approximately 1 percent of Americans, while bipolar disorder impacts up to 2.8 percent, with millions experiencing overlapping symptoms like hallucinations and mood instability that complicate differentiation. Studies indicate misdiagnosis rates as high as 50 percent for schizophrenia and 70 percent for bipolar disorder, frequently leading to incorrect labeling as major depression or other conditions. In one analysis of outpatient settings, over 76 percent of bipolar cases were initially misdiagnosed, often as depression (70 percent of errors) or schizophrenia (20 percent). Racial disparities exacerbate this: Black and Hispanic patients face schizophrenia diagnoses at rates two to three times higher than white counterparts, potentially due to biases in symptom interpretation.
Laguna’s tests aim to mitigate these issues by providing objective, biomarker-driven insights, enabling earlier interventions that could improve outcomes and cut healthcare costs associated with prolonged uncertainty. Independent research supports the need: A 2021 GenomeWeb report highlighted the 18-gene panel’s 83-88 percent accuracy in initial trials, with potential for even higher precision in unmedicated or younger patients, though further replication in diverse cohorts is ongoing.
Company Momentum and Broader Market Context
Founded by psychiatric genomics expert Marquis P. Vawter and life sciences veteran Terry W. Osborn, Laguna has secured National Institute of Mental Health grants and collaborates with institutions like the University of California-Irvine and University of Iowa. The firm is now pursuing seed funding to validate lab-developed tests under CAP/CLIA standards and launch FDA clinical trials, signaling readiness for commercialization.
The innovation arrives as the global mental health diagnostics sector expands rapidly, projected to reach $623 billion by 2032, driven by increasing prevalence—37 million people worldwide live with bipolar disorder alone—and advancements in AI-assisted tools. Antipsychotic markets, closely tied to accurate SZ/BD diagnosis, are forecasted to grow from $19.45 billion in 2024 to $41.21 billion by 2034. In the U.S., behavioral health spending is set to hit $151.62 billion by 2034, fueled by telehealth and stigma reduction efforts.
Implications for Psychiatry and Patient Care
This patent not only fortifies Laguna’s intellectual property but also underscores a paradigm shift toward biomarker-led psychiatry, where tests like these could prevent the 39 percent overall misdiagnosis rate seen in severe psychiatric cases. By enabling precise early detection, the technology holds promise for tailored therapies, reduced trial-and-error with medications, and better equity in care, particularly for underserved populations. As validation advances, Laguna’s approach could redefine standards, offering clinicians reliable data to guide decisions in a field long reliant on observation. For more details, visit the company’s platform or contact its leadership.
